Independently-conducted studies confirm significant bioavailability of orally delivered insulin

ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP) announced that it has received reports of significant bioavailability of orally delivered insulin in two independently-conducted animal studies.  The studies, which confirm earlier findings, were performed as part of on-going work with commercial collaborators that are evaluating Access' Cobalamin™ Oral Drug Delivery Technology.

Access previously reported that its novel Cobalamin-coated insulin containing nanoparticle formulations delivered orally provided a pharmacological response (lowering of blood glucose levels in animal models) equivalent to greater than 80% of that achieved by insulin delivered subcutaneously. The Company believes the substantial oral bioavailability found underscores the formulation's potential for clinical development and ultimate commercialization. Additionally, Access believes that its Cobalamin Oral Drug Delivery Technology has broad application to proteins, small molecule drugs, hormones, and potentially sRNAi therapeutics.  

In addition to insulin, adaptation of this technology has provided a Cobalamin human growth hormone (HGH) formulation that has demonstrated good efficacy, represented by more than 25% improvement in weight gain, when given orally in an established animal model. Access continues moving its insulin and HGH products towards clinical development, while submitting additional patents surrounding both formulations.

"We remain excited about the potential of our Cobalamin oral drug delivery technology, and the positive data being generated," stated Jeff Davis, CEO of Access Pharmaceuticals, Inc.

Access' worldwide-exclusive patented Cobalamin technology utilizes the body's natural vitamin B12 oral uptake to facilitate oral absorption of pharmaceuticals by a "Trojan horse" mechanism. This technology platform provides Access with the ability to develop a number of different formulations with improved benefits for various disease applications.

"We have several ongoing discussions with other companies regarding the application of our oral drug delivery options for their promising new drugs.  Additionally, we continue exploring ways to move this to a proof-of-concept human trial as quickly as possible," commented Phillip Wise, Access' Vice President of Business Development and Strategy.

SOURCE Access Pharmaceuticals, Inc.